Empowering Patients To
change their lives
Neuspera® Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. The company’s proprietary Mid-Field Powering Technology allows devices to be significantly smaller, implanted deeper, and more reliable than other miniaturized neuromodulation technologies. The Neuspera platform will provide patients and physicians new, and potentially earlier, treatment options that are less invasive and more adaptable. These therapeutic alternatives may help patients restore their health and well-being for a better quality of life.
Steffen Hovard is a seasoned medical device executive with 15 years of experience in urology and uro-gyncology. He spent 20 years with Coloplast with various leadership assignments across both commercial and R&D functions, and for 8 years he led President of Coloplast Interventional Urology. This included leadership responsibility for four business areas within urological devices (class I, II, and III) including 900 employees across 19 countries and $300M revenue. Steffen serves on the board of several medical devices companies in both the US and internationally – with a focus on venture and private equity backed companies. Apart from his operational roles, Steffen served on the Boards of both Medical Alley Association and AdvaMed for several years, and he remains an active industry advocate.
He holds Bachelor and Master Degrees in marketing & strategy from Copenhagen Business School in Denmark.
Melissa Farina has over 20 years of experience in corporate finance, accounting, and investor relations. The vast majority of her career has been spent at medical device companies including Beckton Dickinson and LivaNova where she steadily rose up the ranks to executive leadership. She has a proven ability to achieve business objectives through strong business development acquisitions, robust strategic planning, and diligent execution.
She holds an MBA from Rice University and a BS in Business Administration in Finance from Bryant University.
Dr. Steven Siegel is an internationally recognized expert and pioneer in the evolution of Sacral Neuromodulation, having participated in multi-center clinical trials with Urosystems in the late 1980’s when he was the Head of the Section of Female Urology and Urodynamics at the Cleveland Clinic. After the therapy was acquired by Medtronic in the early 1990’s, he participated in the pivotal “103” trials and publications, and helped present the data from those studies to the FDA, leading to Interstim’s original approval for the indication of Urinary Urge Incontinence in 1997. He was instrumental in broadening acceptance and clinical application of the therapy, teaching hundreds of physicians the hows and whys of Sacral Neuromodulation all over the world. He was a founding member of the International Society of Pelvic Neuromodulation, which later merged with the Society of Female Urology and Urodynamics, and played a major role in the merged group’s programming related to the therapy for over a decade. More recently, he was the National Principle Investigator for the InSite Trial, and lead author in many of the publications related to that study. He has recently retired from his clinical practice where he specialized in FPMRS, and served as the Director of the Minnesota Urology Centers for Female Urology and Continence Care since 1993. He has trained over 30 fellows associated with that program. Dr. Siegel also served as the business section editor for the Urology Practice journal from its inception until 2020. He has been the recipient of a number of awards including: AUGS’ National Association for Continence “Continence Care Champion” award in 2018, the Christina Manthos Award for extraordinary mentoring of female urologists from the Society of Women in Urology in 2011, and the David C. Utz Award for Urological Advancement and Innovation from the Minnesota Urological Society in 2002. Dr. Siegel is a Past President of the North Central Section of the American Urological Association (2010), and former board member and Chairman of the Practice Standards Committee of the SUFU. Dr. Siegel graduated from the University of Michigan Medical School and completed his urology residency at the Cleveland Clinic in 1986.
Alexander J. Yeh is Founder, CTO, and Director of Neuspera® Medical Inc. His areas of specialty include wireless power transfer, neurophysiology, RFIC design, wireless communications, and semiconductor packaging.
Alex founded Neuspera to translate the work he advanced during his Ph.D. candidacy at Stanford University. He successfully developed devices and conducted experiments that demonstrated midfield power transfer to deeply implanted miniature devices in preclinical models as outlined in his dissertation, “Wireless Powering and Communications for mm-Sized Pacemakers, Sensors, Neuromodulators, And Optogenetics.” At Neuspera, this fundamental technology has been adapted to human use under his leadership.
Prior to joining Stanford, he was a researcher in communication algorithms for 60 GHz wireless systems and worked as an engineer in a startup, TagArray, developing UWB RFID products.
Alex has a M.S. and Ph.D. from Stanford University in Electrical Engineering, and has a BS in Electrical Engineering and BA in Economics from University of California – Los Angeles. He is named in over 100 patents, patent applications, and academic papers related to implantable medical devices. He also serves on the board of Greenliant Systems, Ltd, a leading global supplier of solid-state storage solutions for industrial, automotive, and medical applications.
Andrina Hougham has 30 years of medical device and pharmaceutical experience in the areas of clinical research, reimbursement, regulatory affairs, and product development. Andrina was the VP of Clinical Research, Reimbursement, and Regulatory Affairs for the Neuromodulation business at Medtronic. These functions supported the global growth of the Neuromodulation business to over $2B in revenue through innovative evidence development that drove timely, differentiated and sustainable global market access. While at Medtronic, she was also the VP of Clinical Research for the Cardiac Rhythm Disease Management organization. In addition, she led a cross-functional product development team responsible for bringing a breakthrough Cardiac Disease Management System to the marketplace and an initiative to provide healthcare to economically disadvantaged patients in Medellin, Colombia. Prior to Medtronic, Andrina developed her clinical research experience at 3M Pharmaceuticals where she worked across all phases of clinical trials on New Drug Applications to achieve product approvals in multiple therapeutic areas.
Andrina has a Masters of Healthcare Administration from the University of Minnesota and a BA in Biochemistry and Molecular Biology from the University of California at Santa Barbara.
Steve Schellenberg has been in the active implantable industry since 1995. He has led operations at multiple early stage companies transitioning through to commercialization and acquisition. He was Director of Operations at Epicor Medical, and Director of Manufacturing Engineering at Spinal Modulation, both acquired by St. Jude Medical (now Abbott). Steve was also VP of Operations at Intrapace Inc. where he helped lead the development and building of operations in support of an implantable neurostimulator intended for the treatment of obesity, resulting in CE mark approval and successful OUS Clinical Trial.
Steve is an expert in electronics assembly and test, design for manufacturing, and hermetic welding. He is well versed in packaging, sterilization, and quality systems. He has built the infrastructure to support product development, regulatory approvals, clinical trials, and commercialization for multiple enterprises. Steve has a BS in Mechanical Engineering from California State University at Chico.